Unknown PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT03576287

Apremilast as Anti-pruritic Treatment in Patients With Prurigo Nodularis

Sponsor: Tanja Todberg, MD

Updated 5 times since 2018 Last updated: Jul 2, 2018 Started: Jul 1, 2017 Primary completion: Dec 1, 2019 Completion: Dec 1, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03576287, this PHASE1/PHASE2 trial focuses on Prurigo Nodularis and remains ongoing. Sponsored by Tanja Todberg, MD, it has been updated 5 times since 2017, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1/PHASE2

Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE1_PHASE2
Aug 2020 — Jan 2021 [monthly]

Unknown Status PHASE1_PHASE2

Status: Recruiting → Unknown Status
Aug 2018 — Aug 2020 [monthly]

Recruiting PHASE1_PHASE2

First recorded

Jul 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tanja Todberg, MD

Data source: University of Copenhagen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hellerup, Denmark